Skip to main content
. 2012 Feb;167(2):330–337. doi: 10.1111/j.1365-2249.2011.04504.x

Fig. 3.

Fig. 3

Differences in senescence and immunological characteristics in graft biopsies from kidney transplant recipients (KTR) under belatacept or cyclosporin A (CsA) treatment. (a) Photomicrograph of tissue architecture of a representative kidney biopsy at pre-implantation, stained by periodic acid Schiff (PAS technique) (×200). (b) Histological image of kidney transplant recipient biopsy from a patient receiving belatacept at 12 months post-transplant, stained by PAS technique (×200). (c) Photomicrograph of kidney transplant recipient biopsy from a patient under CsA treatment at 12 months post-transplant, stained by PAS technique (×200). (d) p16INK4a-expression in kidney biopsy at pre-implantation (×520). (e) p16INK4a-expression in transplant recipient biopsy from a patient receiving belatacept at 12 months post-transplant (×520). (f) p16INK4a- expressing cells in transplant recipient biopsy from a patient under CsA treatment at 12 months post-transplant (×520). (g) CD16+ (in pink)/indoleamine 2, 3-dioxygenase (IDO+) (in brown) expression in kidney biopsy at pre-implantation (×520). (h) CD16+/IDO+-expressing cells in transplant recipient biopsy from a patient receiving belatacept at 12 months post-transplant (×520). (i) CD16+/IDO+ expression in transplant recipient biopsy from a patient under CsA treatment at 12 months post-transplant (×520). (j) Forkhead box protein 3 (FoxP3) expression in kidney biopsy at pre-implantation (×520). (k) FoxP3+-expressing regulatory T cells in transplant recipient biopsy from a patient receiving belatacept at 12 months post-transplant (×520). (l) FoxP3 expression in transplant recipient biopsy from a patient under CsA treatment at 12 months post-transplant (×520). (m) Interleukin (IL)-17A-producing CD4 T cells [CD4+ (in brown)/IL-17A+ (in pink)] cells in kidney biopsy at pre-implantation (×520). (n) IL-17A-producing CD4 T cells in transplant recipient biopsy from a patient receiving belatacept at 12 months post-transplant (×520). (o) IL-17A-producing CD4 T cells in transplant recipient biopsy from a patient under CsA treatment at 12 months post-transplant (×520). Arrows depict immunoreactive cells.